Top Markets
Coin of the day
AbbVie Inc. AbbVie Inc.

AbbVie Inc.

ABBV
Pozycja w akcjach #27
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery,... AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
Cena akcji
$263.25
Kapitalizacja rynkowa
$465.10B
Zmiana (1 dzień)
-0.68%
Zmiana (1 rok)
18.26%
Kraj
US
Handel AbbVie Inc. (ABBV)

Kategoria

Wskaźnik P/S dla AbbVie Inc. (ABBV)
Wskaźnik P/S na dzień September 2026 TTM: 7.18
Według najnowszych raportów finansowych i ceny akcji AbbVie Inc., obecny wskaźnik P/S (TTM) wynosi 7.18. Na koniec 2024 wynosił 5.58.
Historia wskaźnika P/S dla AbbVie Inc. od 2009 do 2026
Wskaźnik P/S na koniec każdego roku
Rok Wskaźnik P/S Zmień
2026 (TTM) 7.18 7.34%
2025 6.69 19.89%
2024 5.58 10.63%
2023 5.04 2.31%
2022 4.93 15.61%
2021 4.26 9.36%
2020 3.90 -1.07%
2019 3.94 -9.12%
2018 4.34 -20.71%
2017 5.47 38.08%
2016 3.96 -5.93%
2015 4.21 -19.47%
2014 5.23 17.09%
2013 4.47 52.37%
2012 2.93 -9.61%
2011 3.24 -10.35%
2010 3.62 -9.11%
2009 3.98 0.00%
Wskaźnik P/S dla podobnych firm lub konkurentów
Firma Wskaźnik P/S Różnica wskaźnika P/S Kraj
13.45 87.29%
US
6.55 -8.74%
US
4.66 -35.13%
CH
5.39 -24.98%
US
5.52 -23.13%
CH